Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Fischer

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Nature Chemical Biology|July 22, 2008
Turning down tau phosphorylationPeter M Fischer
Trends in Pharmacological Sciences|April 22, 2008
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiologyShudong Wang, Peter M Fischer
Current Pharmaceutical Design|May 17, 2005
Strategies for the design of potent and selective kinase inhibitorsCampbell McInnes, Peter M Fischer
Nature Reviews. Drug Discovery|June 2, 2007
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseasesMichael P Mazanetz, Peter M Fischer
Expert Opinion on Investigational Drugs|June 5, 2003
CDK inhibitors in clinical development for the treatment of cancerPeter M Fischer, Athos Gianella-Borradori
Expert Opinion on Investigational Drugs|May 11, 2005
Recent progress in the discovery and development of cyclin-dependent kinase inhibitorsPeter M Fischer, Athos Gianella-Borradori
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 10, 2002
Liquid-phase peptide synthesis on polyethylene glycol (PEG) supports using strategies based on the 9-fluorenylmethoxycarbonyl amino protecting group: application of PEGylated peptides in biochemical assaysPeter M Fischer, Daniella I Zheleva
Nature|February 27, 2004
Turning the key on p53David P Lane, Peter M Fischer
Trends in Pharmacological Sciences|June 29, 2004
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?Peter M Fischer, David P Lane
Drug Discovery Today|January 3, 2007
Pharmacological targeting of lysine acetyltransferases in human disease: a progress reportDavid M Heery, Peter M Fischer
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Nature Chemical Biology|July 22, 2008
Turning down tau phosphorylationPeter M Fischer
Trends in Pharmacological Sciences|April 22, 2008
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiologyShudong Wang, Peter M Fischer
Current Pharmaceutical Design|May 17, 2005
Strategies for the design of potent and selective kinase inhibitorsCampbell McInnes, Peter M Fischer
Nature Reviews. Drug Discovery|June 2, 2007
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseasesMichael P Mazanetz, Peter M Fischer
Expert Opinion on Investigational Drugs|June 5, 2003
CDK inhibitors in clinical development for the treatment of cancerPeter M Fischer, Athos Gianella-Borradori
Expert Opinion on Investigational Drugs|May 11, 2005
Recent progress in the discovery and development of cyclin-dependent kinase inhibitorsPeter M Fischer, Athos Gianella-Borradori
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 10, 2002
Liquid-phase peptide synthesis on polyethylene glycol (PEG) supports using strategies based on the 9-fluorenylmethoxycarbonyl amino protecting group: application of PEGylated peptides in biochemical assaysPeter M Fischer, Daniella I Zheleva
Nature|February 27, 2004
Turning the key on p53David P Lane, Peter M Fischer
Trends in Pharmacological Sciences|June 29, 2004
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?Peter M Fischer, David P Lane
Drug Discovery Today|January 3, 2007
Pharmacological targeting of lysine acetyltransferases in human disease: a progress reportDavid M Heery, Peter M Fischer
Pageof 12